Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11528 posts found.

shutterstock_138095450

Valeant stock rises despite weak Q2 results

August 10, 2016 Research and Development, Sales and Marketing Valeant, financial results

Valeant Pharmaceuticals’ share price in pre-market trading has risen 7.44% to $24.12 in the wake of its Q2 results announcement. …
News
biogen_austria_238

Biogen names haemophilia spin-off Bioverativ

August 10, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Biogen, bioverativ

Biogen has announced that Bioverativ will be the name of the standalone spin-off of its haemophilia and other blood disorders …
News
takeda_tokyo_hq

Old CDF drug not recommended in initial NICE guidance due to lack of evidence

August 10, 2016 Research and Development, Sales and Marketing Adcetris, Cancer Drugs Fund, NICE, Takeda, hodgkin's lymphoma

The National Institute for Health and Care Excellence (NICE) has published draft guidance not recommending Takeda’s Adectris (brentuximab vedotin), despite …
News
imlygic_amgen

NICE recommends Amgen’s Imlygic for advanced skin cancer

August 9, 2016 Manufacturing and Production, Sales and Marketing Amgen, Imlygic, NICE, skin cancer

NICE has published its final draft guidance recommending Amgen’s Imlygic (talimogene laherparepvec) for the treatment of advanced melanoma in adults …
News
joseph_papa

Management shake-up at Valeant as Papa expands senior team

August 9, 2016 Manufacturing and Production, Sales and Marketing Valeant, joseph papa, management, shake up

Joseph Papa continues to remodel the plagued Valeant Pharmaceuticals, as a senior management shake-up has seen several new arrivals and …
News

Apellis Pharmaceuticals appoints Dr Robert Kim as CMO

August 8, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Apellis, CMO, GSK, Novartis, appointment

Clinical stage complement immunotherapy company Apellis Pharmaceuticals has named its new chief medical officer as Dr Robert Kim. Kim’s primary …
Appointment
humira_abbott_

AbbVie files lawsuit against Amgen over Humira copy

August 8, 2016 Research and Development, Sales and Marketing AbbVie, Amgen, FDA, Humira, rheumatoid arthritis

Abbvie has filed a patent infringement lawsuit against Amgen over the latter firm’s copy of its Humira (adalimumab) rheumatoid arthritis …
News
test_results

The power of PrEP

August 8, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, PrEP, high court, lifestyle drug

Many among the general public may not have heard about PrEP, or pre-exposure prophylaxis, before last week when a high …
Feature
indiaflag

Opdivo and Keytruda set for India launches by end of year

August 8, 2016 Sales and Marketing India, keytruda, launch, opdivo

Indian cancer patients could be set to receive two of the world’s leading oncology drugs, MSD’s Keytruda and Bristol-Myers Squibb’s …
News
4741451457_6344b99835_z_-_copy

‘Game changer’ asthma pill sees significant reduction in severe symptoms

August 8, 2016 Research and Development, Sales and Marketing Fevipiprant, Novartis, asthma, university of Leicester

A study at the University of Leicester has found that Fevipiprant (QAW039), the first new asthma pill for nearly 20 …
News
merck_and_co

MSD files Lantus biosimilar with FDA

August 8, 2016 Sales and Marketing FDA, Lantus, MK-1293, MSD, application, biosimilar

MSD, known as Merck in the US and Canada, has filed a new drug application with the US Food and …
News
opdivo_1

Shock for BMS as Opdivo misses goal in late-stage lung cancer trial

August 5, 2016 Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Checkmate, lung cancer, opdivo

Bristol-Myers Squibb has announced that its much heralded cancer therapy, Opdivo (nivolumab), failed to meet its primary endpoint of progression-free …
News
novartis_iobmr

NICE recommends Cosentyx in ankylosing spondylitis

August 4, 2016 Research and Development, Sales and Marketing Cosentyx, NICE, Novartis, ankylosing spondylitis

Novartis has announced that the National Institute for Health and Care Excellence (NICE) has recommended Cosentyx (secukinumab) to treat adults …
News
mr058666-web

Merck Q2 results beat analyst estimates

August 4, 2016 Medical Communications, Sales and Marketing Merck, financial results

Germany pharmaceutical firm Merck has announced its fiscal results for Q2 2016, beating analyst estimates with earnings before interest, taxes, …
News
fda2outsideweb

FDA determines Xiamen Origin Biotech wilfully lied to inspectors and customers

August 4, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, Xiamen Origin Biotech

The US Food and Drug Administration (FDA) carried out an inspection of Chinese drug manufacturer  Xiamen Origin Biotech, finding the …
News
The Gateway to Local Adoption Series

Latest content

Trio become latest Symbiosis commercial additions

October 12, 2026

UK immunoglobulin supply faces growing pressure, report warns

October 12, 2026

How will biomarker-led diagnostics reshape respiratory medicine?

October 11, 2026

Five Facts about COPD

October 11, 2026

“That gap between innovation and delivery was what stood out to me most”

October 11, 2026